Who owns ARWR?
Institutional ownership of Arrowhead Pharmaceuticals Inc. from Form 13F, Q2 2026
499 institutional managers reported holding Arrowhead Pharmaceuticals Inc. (ARWR) in Form 13F filings for Q2 2026, with 119,519,507 shares worth $9.7B. The largest reported holder was BlackRock, Inc. Managers that filed both quarters cut a net 1,167,822 shares (-1.0%). 121 opened new positions and 57 sold out.
- Funds holding
- 499
- Value held
- $9.7B
- New / sold out
- 121 / 57
- Net shares, same filers
- -1.0%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of ARWR
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| BlackRock, Inc. | $1.2B | 12.4% | 14,830,553 | Trimmed |
| Avoro Capital Advisors LLC | $926M | 9.5% | 11,355,555 | Added |
| FMR LLC | $655M | 6.7% | 8,039,804 | Added |
| Vanguard Portfolio Management LLC | $518M | 5.3% | 6,351,355 | Trimmed |
| Vanguard Capital Management LLC | $498M | 5.1% | 6,110,953 | Added |
| State Street Corp | $464M | 4.8% | 5,694,640 | Trimmed |
| Norges Bank | $318M | 3.3% | 3,896,536 | New |
| Invesco Ltd. | $317M | 3.2% | 3,883,976 | Added |
| Geode Capital Management, LLC | $299M | 3.0% | 3,530,612 | Trimmed |
| Fred Alger Management, LLC | $269M | 2.8% | 3,301,919 | Trimmed |
| Baker Bros. Advisors LP | $162M | 1.7% | 1,992,783 | Unchanged |
| Siren, L.L.C. | $140M | 1.4% | 1,715,476 | Added |
| Vestal Point Capital, LP | $128M | 1.3% | 1,575,000 | Trimmed |
| Deerfield Management Company, L.p. | $113M | 1.2% | 1,389,055 | Trimmed |
| First Trust Advisors LP | $110M | 1.1% | 1,352,918 | Added |
| Driehaus Capital Management LLC | $110M | 1.1% | 1,350,556 | Added |
| Jupiter Topco LLC | $99.6M | 1.0% | 1,221,596 | First report |
| Northern Trust Corp | $97.2M | 1.0% | 1,192,868 | Trimmed |
| Dimensional Fund Advisors LP | $96.3M | 1.0% | 1,181,608 | Added |
| Goldman Sachs Group Inc | $93.7M | 1.0% | 1,150,007 | Trimmed |
| Bank of America Corp | $92.9M | 1.0% | 1,139,810 | Added |
| Hood River Capital Management LLC | $91.4M | 0.9% | 1,120,747 | Added |
| Holocene Advisors, LP | $90.2M | 0.9% | 1,106,177 | New |
| Morgan Stanley | $88.4M | 0.9% | 1,084,835 | Added |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $78.6M | 0.8% | 964,479 | Trimmed |
Share of 13F holdings is each fund's shares as a share of the 119,519,507 ARWR shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Norges Bank New+$318M
- First Trust Advisors LP Added+$98.1M
- Holocene Advisors, LP New+$90.2M
- FMR LLC Added+$63.0M
- Avoro Capital Advisors LLC Added+$53.4M
- Invesco Ltd. Added+$49.2M
- Dimensional Fund Advisors LP Added+$46.7M
- Two Sigma Investments, LP Added+$44.4M
- 1832 Asset Management L.P. New+$43.9M
- HRT Financial LP New+$40.6M
Biggest sellers in Q2 2026
- BlackRock, Inc. Trimmed-$272M
- State Street Corp Trimmed-$65.3M
- Vanguard Portfolio Management LLC Trimmed-$64.8M
- Geode Capital Management, LLC Trimmed-$63.3M
- D. E. Shaw & Co., Inc. Trimmed-$61.3M
- Vestal Point Capital, LP Trimmed-$57.1M
- Pictet Asset Management Holding SA Trimmed-$57.0M
- Goldman Sachs Group Inc Trimmed-$48.1M
- Renaissance Technologies LLC Trimmed-$46.3M
- UBS Group AG Trimmed-$38.7M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $1.4B and sold $1.4B; 149 added and 154 trimmed.
Schedule 13D and 13G filings on ARWR
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-05-06FMR LLC SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.Schedule 13G
- 2025-08-11STATE STREET CORP SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.Schedule 13G
- 2025-05-13STATE STREET CORP SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.Schedule 13G
- 2025-02-14Sarepta Therapeutics, Inc. SCHEDULE 13D filed by Arrowhead Pharmaceuticals Inc.Schedule 13D
- 2025-02-05STATE STREET CORP SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.Schedule 13G
Questions about ARWR ownership
- Who owns ARWR stock?
- 499 institutional investment managers reported ARWR positions in their Form 13F filings for Q2 2026, holding 119,519,507 shares worth $9.7B in total. BlackRock, Inc. reported the largest position.
- Are funds buying or selling ARWR?
- In Q2 2026, 121 managers opened new ARWR positions, 149 added, 154 trimmed and 57 sold out. Managers that filed in both quarters sold a net 1,167,822 shares.
- How current is this ARWR institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to ARWR by CUSIP. Options are left out. ARWR news and filings · ARWR insider trades · Top funds